Editas Medicine

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.

We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Stock Symbol: EDIT

Stock Exchange: NASDAQ

11 Hurley Street
Cambridge, Massachusetts 02141 USA
AWARDS
  • NextGen Class of 2015
NEWS
The future of Editas Medicine’s EDIT-101 will be determined later in November after a data readout is available. The data could inform the company whether there is a potential commercial path forward.
While worthy advances have recently been made in sickle cell disease, companies such as Graphite Bio, bluebird bio, Vertex Pharmaceuticals and Editas Medicine have loftier ambitions.
Editas is reportedly in “advanced discussions” regarding the sale of its preclinical cancer lineup. The company told BioSpace it has undertaken a strategic review to inform opportunities.
Only weeks after announcing a new chief executive officer and chief medical officer, Editas Medicine reported promising early data for its Phase I/II RUBY trial of EDIT-301 for severe sickle cell disease (SCD).
Five weeks after taking the reins as CEO of CRISPR-focused Editas Medicine, Gilmore O’Neill fulfilled his first task, appointing a new chief medical officer.
Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.
U.S. Food and Drug Administration(FDA) has granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
Editas Medicine snagged Rare Pediatric Disease designation for its experimental beta thalassemia gene therapy, while VBL received Fast Track designation for an ofra-vec combination in ovarian cancer.
O’Neill, who has served as chief medical officer at Sarepta Therapeutics since 2018, said he is excited about the potential of Editas’ pipeline.
JOBS
IN THE PRESS